Andrew M Heitzer1, Alexandra M Villagran1, Kimberly Raghubar1, Austin L Brown2, Miranda L Camet3, M Douglas Ris1, Jenny H Hanning1, M Fatih Okcu2, Arnold C Paulino4, Murali Chintagumpala2, Lisa S Kahalley5. 1. Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, TX, USA. 2. Department of Pediatrics, Section of Hematology Oncology, Baylor College of Medicine, Houston, TX, USA. 3. Texas Children's Hospital Audiology Department, 17580 Interstate 45 South, Suite WM. 0360, The Woodlands, TX, 77384, USA. 4. Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, TX, USA. lskahall@texaschildrens.org.
Abstract
PURPOSE: Survivors of pediatric embryonal brain tumors (BT) are at high risk for sensorineural hearing loss (SNHL) associated with neurocognitive decline. However, previous studies have not assessed the relationship between SNHL and adaptive functioning. We examined neurocognitive and adaptive functioning in patients with and without SNHL. METHODS: Participants included 36 patients treated for an embryonal BT with craniospinal irradiation (CSI) and cisplatin chemotherapy who were assessed 6.7 years post-treatment on average. The impact of SNHL on neurocognitive performance and parent-rated adaptive functioning was assessed in univariate and multivariate analyses. RESULTS: There were 17 cases with SNHL (mean age at evaluation = 14.4) and 19 cases with NH (mean age at evaluation = 13.8). After accounting for age at diagnosis and additional covariates in multivariable analyses, SNHL was associated with worse overall intellectual functioning (p = 0.027) and perceptual reasoning (p = 0.016) performance. There was no effect of SNHL on adaptive functioning in multivariable models. Age at diagnosis and sex were associated with performance on neurocognitive measures. CONCLUSIONS: SNHL in pediatric embryonal BT is associated with increased risk for neurocognitive deficits in conjunction with other demographic and treatment-related factors.
PURPOSE: Survivors of pediatric embryonal brain tumors (BT) are at high risk for sensorineural hearing loss (SNHL) associated with neurocognitive decline. However, previous studies have not assessed the relationship between SNHL and adaptive functioning. We examined neurocognitive and adaptive functioning in patients with and without SNHL. METHODS:Participants included 36 patients treated for an embryonal BT with craniospinal irradiation (CSI) and cisplatin chemotherapy who were assessed 6.7 years post-treatment on average. The impact of SNHL on neurocognitive performance and parent-rated adaptive functioning was assessed in univariate and multivariate analyses. RESULTS: There were 17 cases with SNHL (mean age at evaluation = 14.4) and 19 cases with NH (mean age at evaluation = 13.8). After accounting for age at diagnosis and additional covariates in multivariable analyses, SNHL was associated with worse overall intellectual functioning (p = 0.027) and perceptual reasoning (p = 0.016) performance. There was no effect of SNHL on adaptive functioning in multivariable models. Age at diagnosis and sex were associated with performance on neurocognitive measures. CONCLUSIONS:SNHL in pediatric embryonal BT is associated with increased risk for neurocognitive deficits in conjunction with other demographic and treatment-related factors.
Authors: Ann M Maddrey; Jon A Bergeron; Elizabeth R Lombardo; Noelle K McDonald; Arlynn F Mulne; Paul D Barenberg; Daniel C Bowers Journal: J Neurooncol Date: 2005-05 Impact factor: 4.130
Authors: Jason M Ashford; Kelli L Netson; Kellie N Clark; Thomas E Merchant; Victor M Santana; Shengjie Wu; Heather M Conklin Journal: J Neurooncol Date: 2014-05 Impact factor: 4.130
Authors: Johnnie K Bass; Chia-Ho Hua; Jie Huang; Arzu Onar-Thomas; Kirsten K Ness; Skye Jones; Stephanie White; Shaum P Bhagat; Kay W Chang; Thomas E Merchant Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544
Authors: Derek S Tsang; Laurence Kim; Zhihui Amy Liu; Laura Janzen; Mohammad Khandwala; Eric Bouffet; Normand Laperriere; Hitesh Dama; Dana Keilty; Tim Craig; Vijay Ramaswamy; David C Hodgson; Donald Mabbott Journal: Neuro Oncol Date: 2021-03-25 Impact factor: 12.300
Authors: Ade Oyefiade; Iris Paltin; Cinzia R De Luca; Kristina K Hardy; David R Grosshans; Murali Chintagumpala; Donald J Mabbott; Lisa S Kahalley Journal: J Clin Oncol Date: 2021-04-22 Impact factor: 50.717